Angiogenesis has been associated with clinicopathological factors and features of biological aggressiveness in urothelial cancer.^1,2 Although several agents targeting the vascular endothelial growth factor (VEGF) pathway have been investigated in phase 1 and 2 trials in advanced urothelial cancer and as maintenance,^1,3–5 the overall clinical benefit has been small, with occasional disease stabilisation seen in some patients.^1,3

中文翻译：

---

抗血管生成抑制尿路上皮癌

血管生成与尿路上皮癌的临床病理因素和生物学侵袭性特征有关。^1,2尽管在晚期尿路上皮癌的第1期和第2期试验中已经研究了几种靶向血管内皮生长因子（VEGF）途径的药物，并且作为维持^药物，但^1,3–5的总体临床获益很小，偶而疾病稳定在某些患者中见过。^1,3